France August 5, 2024BENEFIT trial: isatuximab, lenalidomide, and dexamethasone +/- bortezomib in newly diagnosed myeloma
France July 18, 2024BENEFIT trial: isatuximab, lenalidomide, and dexamethasone +/- bortezomib in newly diagnosed myeloma
